Bio Roundup: Mylan’s Shock, Hillary’s 3%, Duchenne Lessons & More
Xconomy
AUGUST 26, 2016
The company shares rights to its lead drug enzalutamide (Xtandi) with Astellas Pharma and its second drug, talazoparib, a type of cancer treatment called a PARP inhibitor, awaits crucial Phase 3 data next year. The company gave no reason for the rejection. Whether Medivation will be worth the price remains to be seen.
40 
Let's personalize your content